Table 3.

Clinical characteristics of patients with melanoma and objective response

No.	Age	Sex	AJCC stage	Primary site	Initial metastatic sites*	Cycles of treatment	Treatment site response	Non-treatment site regional response	Best overall response	Time to response (months)	Response duration (months)	Overall survival (months)
1	64	F	IV M1b	Left forearm	Bilateral lower lobe lung	3	CLR	CLR	CR	1	12	66.4
2	67	M	IIIC	Left side of head	-	3	CLR	CLR	CR	4	7	64.2+
3	46	F	IV M1c	Back	perihilar region of lungs, liver, uterus	2	PLR	N/A	PR	1	2	8.5
4	63	F	IIIB N2c	Left leg	-	2	PLR	PLR	PR	3	4	44.9+
5	60	F	IV M1A	Right frontal scalp	Distal skin site	2	CLR	CLR	CR	2	4	6.6
6	87	M	IIIC N2c	Right foot (plantar)	-	6	PLR	SD	SD	1	0	15.5
7	71	M	IV M1c	Eye	Liver	1	CLR	N/A	PD	1	2	2.3
8	74	M	IIIC N3	Left lower back	-	1	CLR	N/A	CR	8	2	38.7+
9	84	M	IIIB N2c	Left foot	-	1	CLR	SD	CR	6	1	6.0**
10	85	M	IV M1c	Left arm	Anterior mediastinum	1	CLR	CLR	CR***	1	8	22.5+
11	69	M	IV M1c	Right forehead	Bone, lung	1	CLR	N/A	CR	1	6	20.6+

Abbreviations: M, male; F, female; AJCC, American Joint Committee on Cancer; CLR, complete local response; PLR, partial local response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; N/A, not available or not applicable.

^*In addition to skin, present at the time of study entry.

^**This patient died of progression of myelodysplasia to leukemia (unrelated tumor death).

^***The metastatic lesion was treated with cyberknife.